Advertisement

Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index

  • Yasufumi Kawasaki
  • Shun-ichi Kimura
  • Hirofumi Nakano
  • Kiyomi Mashima
  • Yuya Shirato
  • Shin-ichiro Kawaguchi
  • Yumiko Toda
  • Shin-ichi Ochi
  • Takashi Nagayama
  • Daisuke Minakata
  • Ryoko Yamasaki
  • Kaoru Morita
  • Masahiro Ashizawa
  • Chihiro Yamamoto
  • Kaoru Hatano
  • Kazuya Sato
  • Iekuni Oh
  • Shin-ichiro Fujiwara
  • Ken Ohmine
  • Shinichi Kako
  • Kazuo Muroi
  • Yoshinobu KandaEmail author
Original Article
  • 55 Downloads

Abstract

Neutropenia is a major risk factor for opportunistic infections in patients with acute myeloid leukemia (AML) who undergo chemotherapy. In the present study, we retrospectively compared the D-index, which reflects both the depth and duration of neutropenia, between two different chemotherapy regimens for AML. Sixty-seven patients with AML were included: 37 received an induction regimen of daunorubicin (DNR) and cytarabine followed by consolidation therapies consisting of standard-dose cytarabine (SDAC) and other antineoplastic agents; the remaining 30 received idarubicin (IDR) and cytarabine as remission induction therapy followed by high-dose cytarabine (HDAC). The duration of neutropenia was shorter, but the D-index was higher, with IDR than with DNR. The total D-index during the entire consolidation therapies was significantly higher with SDAC than with HDAC. In conclusion, the neutropenia profile differs between treatment regimens, and thus, physicians should plan the management of infectious complications according to the neutropenia profile for each regimen.

Keywords

D-index Acute myeloid leukemia Neutropenia Anthracycline High-dose cytarabine 

Notes

Acknowledgements

We thank the patients for their participation in the study.

Author contributions

YK contributed to the study design, data analysis, and manuscript preparation. SK, HN, KM, YS, SK, YT, SO, TN, DM, RY, KM, MA, CY, KH, KS, IO, SF, KO, SK, KM and YK reviewed the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.CrossRefGoogle Scholar
  2. 2.
    Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39(Suppl 1):32–7.CrossRefGoogle Scholar
  3. 3.
    Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol. 2009;27:3849–54.CrossRefGoogle Scholar
  4. 4.
    Kimura S, Wada H, Ishihara Y, Kawamura K, Sakamoto K, Yamasaki R, et al. D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine. Hematology. 2014;19:107–12.CrossRefGoogle Scholar
  5. 5.
    Kimura S, Oshima K, Sato K, Sato M, Terasako K, Nakasone H, et al. Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010;16:1355–61.CrossRefGoogle Scholar
  6. 6.
    Miyawaki S. Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. Int J Hematol. 2012;96:171–7.CrossRefGoogle Scholar
  7. 7.
    Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117:2366–72.CrossRefGoogle Scholar
  8. 8.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefGoogle Scholar
  9. 9.
    Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117:2358–65.CrossRefGoogle Scholar
  10. 10.
    Sano H, Kobayashi R, Suzuki D, Hori D, Kishimoto K, Kobayashi K. Impact of the D-index deduced from duration and intensity of neutropenia following chemotherapy on the risk of invasive fungal infection in pediatric acute myeloid leukemia. Int J Hematol. 2018;108:85–90.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Yasufumi Kawasaki
    • 1
  • Shun-ichi Kimura
    • 2
  • Hirofumi Nakano
    • 1
  • Kiyomi Mashima
    • 1
  • Yuya Shirato
    • 1
  • Shin-ichiro Kawaguchi
    • 1
  • Yumiko Toda
    • 1
  • Shin-ichi Ochi
    • 1
  • Takashi Nagayama
    • 1
  • Daisuke Minakata
    • 1
  • Ryoko Yamasaki
    • 1
  • Kaoru Morita
    • 1
  • Masahiro Ashizawa
    • 1
  • Chihiro Yamamoto
    • 1
  • Kaoru Hatano
    • 1
  • Kazuya Sato
    • 1
  • Iekuni Oh
    • 1
  • Shin-ichiro Fujiwara
    • 1
  • Ken Ohmine
    • 1
  • Shinichi Kako
    • 2
  • Kazuo Muroi
    • 1
  • Yoshinobu Kanda
    • 1
    • 2
    Email author
  1. 1.Division of Hematology, Department of MedicineJichi Medical UniversityShimotsukeJapan
  2. 2.Division of HematologyJichi Medical University Saitama Medical CenterSaitamaJapan

Personalised recommendations